Last kr127.50 SEK
Change Today -1.25 / -0.97%
Volume 139.0K
MVIRB On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
OTC US
Frankfurt
As of 11:30 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

medivir ab-b shs (MVIRB) Snapshot

Open
kr128.75
Previous Close
kr128.75
Day High
kr130.50
Day Low
kr127.25
52 Week High
06/12/14 - kr151.00
52 Week Low
11/4/13 - kr77.75
Market Cap
4.0B
Average Volume 10 Days
141.6K
EPS TTM
kr19.85
Shares Outstanding
30.6M
EX-Date
--
P/E TM
6.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVIR AB-B SHS (MVIRB)

Related News

No related news articles were found.

medivir ab-b shs (MVIRB) Related Businessweek News

No Related Businessweek News Found

medivir ab-b shs (MVIRB) Details

Medivir AB, a research-based specialty pharmaceutical company, develops and markets pharmaceuticals for the treatment of infectious diseases in the Nordic region. It focuses on the research and development of antiviral pharmaceuticals primarily in the hepatitis C area; and other areas, such as bone-related disorders and neuropathic pain. The company also supplies prescription pharmaceuticals, including 16 prescription pharmaceuticals in different therapeutic areas, including Mollipect, Teovent, and Theo-Dur in respiratory organs; Probecid for gout; Nitroglycerin BioPhausia, Digoxin BioPhausia, and Suscard for cardiovascular system; simeprevir for liver disease; Laxabon and Egazil for gastrointestinal system; Xerclear for cold sores; Lithionit and Adasuve for psychiatry; Paraflex for the musculoskeletal system; Citodon and Morfin Special for pain; and Solvezink for zinc deficiency. Medivir AB is headquartered in Stockholm, Sweden.

142 Employees
Last Reported Date: 08/21/14

medivir ab-b shs (MVIRB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medivir ab-b shs (MVIRB) Key Developments

Medivir Reports Earnings Results for the Second Quarter and Six Months Ended June 2014

Medivir reported earnings results for the second quarter and six months ended June 2014. For the quarter, the company's net turnover was SEK 564.0 million against SEK 40.7 million a year ago. Operating profit before depreciation and amortisation (EBITDA) was SEK 424.4 million against LBITDA of SEK 46.9 million a year ago. Operating profit (EBIT) was SEK 416.2 million against LBIT of SEK 62.0 million a year ago. Profit before tax was SEK 418.4 million against loss before tax of SEK 62.1 million a year ago. Profit after tax was SEK 327.8 million or SEK 10.28 diluted per share against loss after tax of SEK 63.7 million or SEK 2.04 diluted per share a year ago. Cash flow from operating activities was SEK 88.7 million against cash flow used in operating activities of SEK 8.3 million a year ago. For the six months, the company's net turnover was SEK 772.2 million against SEK 218.8 million a year ago. Operating profit before depreciation and amortisation (EBITDA) was SEK 521.2 million against SEK 43.6 million a year ago. Operating profit (EBIT) was SEK 504.9 million against SEK 14.7 million a year ago. Profit before tax was SEK 508.7 million against SEK 14.5 million a year ago. Profit after tax was SEK 611.7 million or SEK 19.18 diluted per share against SEK 7.5 million or SEK 0.24 diluted per share a year ago. Cash flow from operating activities was SEK 31.0 million against cash flow used in operating activities of SEK 27.2 million a year ago.

Medivir Mulls Acquisition

Medivir AB (OM:MVIR B) is looking for acquisitions. Rein Pirr, Executive Vice President of Corporate Affairs & Investor Relations at Medivir AB said, "We have been talking internally, looking to exploit our drug discovery expertise and our expertise in antiviral discovery and development, and have been talking about RSV for some time. We recognized, in the Boehringer Ingelheim program, the opportunity to rapidly advance our program into lead optimization through this acquisition; and is entirely consistent with our strategic intent to continue to enhance our R&D pipeline through building and acquiring high value commercial opportunities, such as this one."

Medivir AB Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-18-2014

Medivir AB Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-18-2014 . Venue: Bank of America Merrill Lynch Financial Centre, London, United Kingdom.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVIRB:SS kr127.50 SEK -1.25

MVIRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVIRB.
View Industry Companies
 

Industry Analysis

MVIRB

Industry Average

Valuation MVIRB Industry Range
Price/Earnings 6.1x
Price/Sales 3.7x
Price/Book 2.5x
Price/Cash Flow 5.9x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVIR AB-B SHS, please visit www.medivir.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.